NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. The company is headquartered in Fort Myers, Florida.
| Revenue (TTM) | $745.97M |
| Gross Profit (TTM) | $321.51M |
| EBITDA | $4.27M |
| Operating Margin | -9.34% |
| Return on Equity | -11.60% |
| Return on Assets | -2.64% |
| Revenue/Share (TTM) | $5.80 |
| Book Value | $6.39 |
| Price-to-Book | 2.38 |
| Price-to-Sales (TTM) | 2.49 |
| EV/Revenue | 2.998 |
| EV/EBITDA | 945.39 |
| Quarterly Earnings Growth (YoY) | 130.60% |
| Quarterly Revenue Growth (YoY) | 11.10% |
| Shares Outstanding | $130.21M |
| Float | $118.27M |
| % Insiders | 2.05% |
| % Institutions | 108.25% |
Volatility is currently expanding
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics launched PTEN IHC CDx, the first IHC companion diagnostic test approved by the U.S. FDA for patients with prostate adenocarcinoma.
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will report its second quarter 2026 financial results after the close of U.S. financial markets on Tuesday, July 28, 2026.
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics announced the appointment of Carolyn Starrett to its Board of Directors.
NeoGenomics (NEO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Neo Performance Materials Inc. (NEO:CA) Shareholder/Analyst Call Prepared Remarks Transcript
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics Announces Pricing of Offering of $275 Million Convertible Senior Notes.
The base shelf prospectus is accessible, and the prospectus supplement will be accessible within two business days through SEDAR+ The base shelf prospectus is accessible, and the prospectus supplement will be accessible within two business days through SEDAR+
Strategic partnership positions Greenland Mines to lead exploration while Neo retains equity stake and offtake rights Strategic partnership positions Greenland Mines to lead exploration while Neo retains equity stake and offtake rights
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the Company will participate in the following investor conferences: The 23rd Annual Craig-Hallum Institutional Investor Conference in Minneapolis Investor 1x1 meetings on Thursday, May 28th The Jefferies Global Healthcare Conference 2026 in New York Fireside chat on Thursday, June 4th, at 10:30am EDT, and investor 1x1 meetings A w.
Neo Performance Materials Inc. (NEO:CA) Q1 2026 Earnings Call Transcript
